Launch week offerEnds in00h00m00s
annual Promonthly Pro
Lina Weinert
Research Associate
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (11)
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Background Biomarker-based therapies are increasingly used in cancer patients outside clinical trials. Systematic assessment of patient-reported outcomes (PRO) is warranted to take patients’ perspectives during biomarker-based therapies into consideration. We assessed the feasibility of an electronic PRO assessment via a smartphone application. Methods An interdisciplinary expert panel developed a smartphone application based on symptom burden and health-related quality of life (HRQoL) metrics reported in a retrospective analysis of 292 neuro-oncological patients. The app included validated assessments of health-related quality of life (HRQoL), the burden of symptoms, and psychological stress. Feasibility and usability were tested in a pilot study. Semi-structured interviews with patients and health care professionals (HCP) were conducted, transcribed, and analyzed according to Mayring´s qualitative content analysis. Furthermore, we assessed compliance and descriptive data of ePROs. Results A total of 14 patients have been enrolled, (9 female, 5 male). A total of 4 HCPs, 9 patients, and 1 caregiver were interviewed regarding usability/feasibility. The main advantages were the possibility to complete questionnaires at home and comfortable implementation in daily life. Compliance was high, for example, 82% of the weekly distributed NCCN distress thermometer questionnaires were answered on time, however, with interindividual variability. We observed a median distress score of 5 (range 0–10, 197 results, n = 12, weekly assessed) and a median Global health score of 58.3 according to the EORTC QLQ-C30 instrument (range 16.7–100, 77 results, n = 12, monthly assessed). Conclusions This pilot study proved the feasibility and acceptance of the app. We will therefore expand its application during biomarker-guided therapies to enable systematic PRO assessments.
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (9)
Mirjam Renovanz
University Hospital Tübingen
Till Nagel
Research Professor of Visual Analytics
Hochschule Mannheim
Peter Eickholz
Goethe University Frankfurt
Christoph Dieterich
Professor of Bioinformatics and Systems Cardiology
University Hospital Heidelberg
Patrick Hennrich
Research Associate
University Hospital Heidelberg
Michel Wensing
Professor of Health Services Research and Implementation Science
UniversitätsKlinikum Heidelberg
Jussi P. Posti
Associate Professor (Tenure Track, phase 2/2)
University of Turku
Petra Knaup
University Hospital Heidelberg
Nico Pfeifer
Professor
Eberhard Karls Universität Tübingen Mathematisch-Naturwissenschaftliche Fakultät
Make your next move.
Prepare your application
Review drafts before you send them.